Medical Device Clinical Trial Cost: Complete 2026 Budget Breakdown from Early Feasibility Through Pivotal Studies

Why Clinical Trial Cost Is the Biggest Budget Unknown in Medical Devices

Ask any medical device startup what their biggest financial uncertainty is, and the answer is almost always the same: the clinical trial budget. Unlike manufacturing costs, which can be estimated from bill-of-materials analyses, or regulatory fees, which are published by FDA each fiscal year, clinical trial costs vary enormously depending on device type, study design, patient population, number of sites, follow-up duration, and regulatory pathway.

The result is a budgeting problem that too many companies get wrong. Clinical trials for medical devices supporting regulatory submissions typically cost $1 million to $20 million or more, with complex pivotal studies for Class III devices exceeding $50 million in some therapeutic areas. Yet the variance is so wide that two devices in the same risk class can have trial budgets that differ by an order of magnitude.

This guide provides specific, sourced cost figures for every component of a medical device clinical trial in 2026. Use it to build a bottom-up budget estimate, identify cost categories you might be overlooking, and understand where the real opportunities to save money exist.

The Scale of the Problem

Clinical trials represent the single largest cost center in medical device development, consuming an estimated 40-60% of total R&D budgets. According to research from the HHS Assistant Secretary for Planning and Evaluation (ASPE), the average clinical trial program for a complex medical device costs approximately $32.1 million and accounts for 59% of total R&D expenditures.

Yet many companies approach clinical budgeting with inadequate rigor. A frequently cited industry finding is that approximately 43% of trial expenditures may lie in poorly-tracked startup activities alone. Between protocol amendments, enrollment delays, and unanticipated regulatory interactions, actual trial costs routinely exceed initial budgets by 20-40%.

---

When You Actually Need a Clinical Trial

Before spending a single dollar on trial planning, answer this question first: do you actually need a clinical trial?

Many companies overspend because they assume clinical data is required when it may not be. Understanding which regulatory pathways demand clinical evidence -- and which do not -- is the single most impactful cost-saving decision in device development.

510(k) Pathway: Clinical Data Is the Exception, Not the Rule

The 510(k) pathway, which accounts for the vast majority of medical device submissions in the United States, is built on the principle of substantial equivalence. If your device can be shown to be as safe and effective as a legally marketed predicate device through bench testing, performance testing, and non-clinical data alone, no clinical trial is needed.

FDA data shows that fewer than 10-15% of 510(k) submissions include clinical data. For the majority of Class II devices, a well-executed non-clinical testing program is sufficient. Clinical data becomes necessary in the 510(k) context when:

• The device uses new technology not found in any predicate
• Technological characteristics raise new questions of safety or effectiveness
• FDA issues an Additional Information letter specifically requesting clinical data
• The device type has a guidance document or special control mandating clinical evidence
• The manufacturer is making claims that go beyond the predicate's indications for use

Cost implication: If you can clear your device through 510(k) without clinical data, you save the entire trial budget. This is why engaging FDA early through a Pre-Submission (Pre-Sub) meeting is so important.

De Novo Pathway: Clinical Data Is Common but Variable

The De Novo classification process, used for novel low-to-moderate risk devices without a predicate, often requires clinical data but the scope varies enormously. Some De Novo submissions are supported by a small single-arm study of 30-50 patients. Others require more robust evidence approaching pivotal-level data.

Typical De Novo clinical trial cost range: $500K to $5M.

PMA Pathway: Clinical Data Is Essentially Mandatory

For Class III devices requiring Premarket Approval (PMA), clinical trials are almost always required. FDA requires "valid scientific evidence" of safety and effectiveness, which in practice means data from a well-controlled clinical investigation.

Typical PMA clinical trial cost range: $5M to $50M+.

Decision Framework: Do You Need a Clinical Trial?

Scenario	Clinical Trial Needed?	Typical Approach
510(k) with strong predicate, same technology	Unlikely	Non-clinical testing program ($50K-$300K)
510(k) with modified technology, same intended use	Possibly	Pre-Sub meeting to clarify; may need small study ($300K-$2M)
510(k) with new technology or different intended use	Likely	Feasibility + possibly pivotal ($1M-$10M)
De Novo classification request	Usually	Feasibility study ($500K-$3M)
PMA for Class III device	Almost always	Feasibility + pivotal ($5M-$50M+)
Breakthrough Device Designation	Yes, with FDA concurrence	Adaptive/iterative design, potentially streamlined

The Pre-Submission Meeting: Your Highest-ROI Investment

A Pre-Submission (Pre-Sub) meeting with FDA costs nothing in user fees and takes approximately 60-75 days from submission to feedback. Yet it can save hundreds of thousands -- or millions -- of dollars by clarifying whether clinical data is needed and, if so, what study design would satisfy FDA expectations.

File a Q-Submission (Q-Sub) with specific questions about your clinical evidence requirements before committing to a trial protocol. The written feedback FDA provides becomes your development roadmap.

---

Cost by Study Phase

Medical device clinical trials are organized into study phases that reflect the iterative nature of device development. Each phase has distinct objectives, scope, and cost profiles.

Early Feasibility Studies (EFS): $300K - $1.5M

Early feasibility studies are small, iterative first-in-human evaluations conducted primarily under FDA's Early Feasibility Study guidance. They are designed to evaluate device concept, capture preliminary safety data, and inform device design iterations.

Typical scope:

Parameter	Range
Patient count	10-30 patients
Study design	Single-arm, no control group
Number of sites	1-3 sites
Follow-up duration	30 days to 6 months
IDE required	Yes (significant risk devices)
Timeline	9-18 months

Example budget for a 20-patient EFS (illustrative):

Cost Category	Estimated Cost	Notes
Per-patient costs (~$12K each)	$240K	Screening, enrollment, procedures, follow-up
Site startup and activation (2 sites)	$40K	Contracts, training, initiation visits
CRO project management and monitoring	$180K	Study oversight, site monitoring visits
Data management and statistics	$90K	Database design, data entry, analysis
Regulatory and IDE support	$80K	IDE preparation, submission, correspondence
IRB fees and insurance	$90K	IRB review at each site, study insurance
Estimated total	~$720K

This example assumes a relatively straightforward device and procedure. Implantable devices, cardiovascular devices, and devices requiring complex imaging or long-term follow-up will trend toward the higher end of the range.

Pilot / Feasibility Studies: $500K - $5M

Pilot studies (sometimes called traditional feasibility studies) are larger than early feasibility studies and generate data to support pivotal study design decisions. They are common for devices that have already completed early feasibility work and need more data before committing to a large pivotal trial.

Typical scope:

Parameter	Range
Patient count	30-80 patients
Study design	Single-arm or small RCT
Number of sites	3-10 sites
Follow-up duration	3-12 months
IDE required	Typically yes
Timeline	12-24 months

Example budget for a 50-patient pilot study (illustrative):

Cost Category	Estimated Cost	Notes
Per-patient costs (~$18K each)	$900K	More procedures and longer follow-up than EFS
Site startup and management (5 sites)	$150K	Expanded site network
CRO management and monitoring	$400K	More sites, more visits
Data management and statistics	$180K	Larger dataset, more complex analysis
Regulatory and IDE support	$120K	IDE maintenance, amendments
IRB fees and insurance	$150K	More sites = more IRBs (or centralized review)
Independent core lab (if imaging endpoints)	$100K-$300K	Imaging analysis, if applicable
Estimated total	~$2M - $2.2M

Pivotal Studies: $2M - $20M+

Pivotal studies generate the primary clinical evidence for regulatory submissions. They are the definitive trials upon which FDA bases safety and effectiveness determinations for PMA and select 510(k) and De Novo submissions.

Typical scope:

Parameter	Range
Patient count	50-300+ patients
Study design	Single-arm or randomized controlled trial (RCT)
Number of sites	5-20+ sites
Follow-up duration	6 months to 5+ years
IDE required	Yes
Timeline	2-5+ years

Example budget for a 100-patient pivotal study, 12-month follow-up (illustrative):

Cost Category	Estimated Cost	Notes
Per-patient costs (~$25K-$30K each)	$2.5M-$3M	Comprehensive procedures, imaging, follow-up
Site startup and management (10 sites)	$400K	Multi-site activation and maintenance
CRO management and monitoring	$1.2M	Full-service CRO engagement
Data management, statistics, regulatory support	$600K	Complex endpoint analysis, regulatory writing
IRB fees and insurance	$300K	Centralized and site-level IRB
Independent core lab	$200K-$500K	Standardized imaging or endpoint assessment
Clinical events committee (if applicable)	$150K-$300K	Adjudication of safety events
Estimated total	~$5.4M - $6.3M

Large pivotal trials with RCT design, multiple international sites, and extended follow-up can easily exceed $10M and reach $20M+ for complex cardiovascular, orthopedic, or neuromodulation devices.

Study Phase Cost Summary

Study Phase	Patient Count	Sites	Typical Cost Range	Timeline
Early feasibility (EFS)	10-30	1-3	$300K - $1.5M	9-18 months
Pilot / feasibility	30-80	3-10	$500K - $5M	12-24 months
Pivotal	50-300+	5-20+	$2M - $20M+	2-5+ years
Post-market (PMCF / PAS)	Varies	Varies	$500K - $10M+	1-5+ years

---

Recommended Reading

CLIA Waiver for IVDs: Submission Strategy, Study Design, and Dual 510(k) Pathway

IVD & Diagnostics Regulatory2026-04-30 · 12 min read

Detailed Cost Breakdown by Category

Understanding the individual cost components lets you build a bottom-up budget estimate and identify where savings are possible.

Per-Patient Costs: $14,000 - $50,000+ per Enrolled Patient

Per-patient costs are the variable costs that scale with enrollment. They represent the single largest cost category in most device trials.

What drives per-patient cost:

Cost Element	Typical Range per Patient	Notes
Screening and enrollment	$1,500 - $3,000	Patient identification, consent, eligibility assessment
Baseline visit and imaging	$2,000 - $5,000	Pre-procedure workup, baseline assessments
Device implantation / procedure	$5,000 - $15,000+	Procedure costs, hospital stay, operating room time
Follow-up visits (per visit)	$1,500 - $4,000	Number of visits multiplied by per-visit cost
Investigator fees	$2,000 - $5,000	Principal investigator compensation
Patient travel and stipends	$200 - $1,500	Reimbursement for patient participation
Adverse event management	Variable	Can be significant for implantable devices

Detailed per-patient cost example:

For a hypothetical implantable cardiovascular device with 12-month follow-up including 5 post-procedure visits:

Cost Element	Estimated Cost
Screening and enrollment	$2,000
Baseline visit and imaging	$3,000
Procedure and hospitalization	$12,000
Follow-up visits (5 visits at $2K each)	$10,000
Investigator fees	$4,000
Total per patient	~$31,000

At $31,000 per patient, a 60-patient trial costs $1.86 million in patient-related expenses alone, before any site, CRO, or regulatory costs.

Site Startup and Management: $3,500 - $7,500+ per Site

Every clinical trial site incurs fixed startup costs before the first patient is enrolled. These costs are often underestimated because they involve multiple activities spread across several months.

Site Startup Component	Typical Cost per Site
Regulatory and feasibility assessment	$3,000 - $8,000
Contract and budget negotiation	$5,000 - $15,000
IRB submission (site-level or central)	$2,000 - $5,000
Investigator training (GCP and protocol)	$3,000 - $8,000
Site initiation visit	$3,000 - $7,000
Equipment shipping and setup	$1,000 - $5,000
Staff hiring and training	$10,000 - $30,000
Technology and systems setup (EDC, CTMS)	$5,000 - $15,000
Pharmacy and investigational product handling	$1,000 - $5,000
Facilities and overhead	$2,000 - $10,000
Total per site	$35,000 - $108,000

These figures explain why site startup is such a significant cost driver. With 10 sites, startup costs alone can range from $350,000 to over $1 million. Moreover, research has found that approximately 43% of trial expenditures may be attributed to poorly-tracked startup activities, making this one of the most commonly underbudgeted categories.

CRO Project Management and Monitoring: $150K - $3M+

Most medical device sponsors -- particularly startups and mid-size companies -- outsource clinical trial management to a Contract Research Organization (CRO). The medical device CRO market was valued at approximately $9.25 billion in 2025 and is projected to reach $19.9 billion by 2034, reflecting the industry's heavy reliance on outsourced clinical services.

CRO Service	Small Study (EFS)	Medium Study (Pilot)	Large Study (Pivotal)
Project management	$30K - $60K	$80K - $200K	$200K - $500K
Clinical monitoring (site visits)	$60K - $100K	$150K - $400K	$400K - $1M+
Site selection and feasibility	$10K - $25K	$25K - $60K	$60K - $150K
Site initiation and closeout	$15K - $30K	$30K - $80K	$80K - $200K
Regulatory support	$20K - $40K	$40K - $100K	$100K - $300K
Medical monitoring	$15K - $30K	$30K - $80K	$80K - $200K
Total CRO costs	$150K - $285K	$355K - $920K	$920K - $2.35M+

CRO fees vary significantly based on the size and specialization of the CRO. Large full-service CROs (ICON, IQVIA, Medpace, Parexel) charge premium rates, while smaller specialty CROs focused specifically on medical devices often provide better value for device-specific studies.

Data Management and Biostatistics: $50K - $600K

Component	Small Study	Medium Study	Large Study
Electronic Data Capture (EDC) system	$10K - $25K	$25K - $60K	$60K - $150K
Database design and validation	$10K - $20K	$20K - $50K	$50K - $120K
Data entry and query resolution	$5K - $15K	$15K - $40K	$40K - $100K
Statistical analysis plan (SAP)	$10K - $20K	$20K - $40K	$40K - $80K
Final statistical analysis	$10K - $25K	$25K - $50K	$50K - $120K
Medical writing (clinical study report)	$15K - $30K	$30K - $60K	$60K - $150K
Total	$60K - $135K	$135K - $300K	$300K - $720K

Regulatory and IDE Support: $75K - $200K+

IDE preparation is a significant standalone cost that is separate from CRO management fees. The IDE application requires compilation of prior investigations data, a detailed investigational plan, a risk analysis, and manufacturing information.

Regulatory Component	Typical Cost
IDE application preparation	$40K - $100K
FDA correspondence and responses	$15K - $40K
IDE amendments and annual reports	$10K - $30K
Pre-Submission meeting preparation	$10K - $30K
Total	$75K - $200K

This cost does not include preclinical testing that may be required to support the IDE. Preclinical testing (bench testing, animal studies) can add $200K to $2M+ depending on the device.

IRB Fees and Study Insurance: $30K - $300K

Component	Typical Cost
Central IRB review (single submission)	$5K - $15K
Site-level IRB review (per site)	$2K - $5K per site
Continuing review (annual)	$2K - $5K per site per year
Clinical trial insurance	$10K - $50K+
Subject injury coverage	$5K - $30K
Total	$30K - $300K (varies with number of sites and study duration)

Using a central IRB rather than individual site IRBs can reduce this cost substantially, particularly for multi-site studies.

Technology and Systems: $15K - $150K+

Clinical trials require specialized technology systems:

System	Annual License / Setup Cost
Clinical Trial Management System (CTMS)	$10K - $40K
Electronic Data Capture (EDC)	$10K - $50K
Electronic Trial Master File (eTMF)	$5K - $25K
Interactive Response System (IxRS) for randomization	$5K - $20K
Safety / pharmacovigilance database	$5K - $25K
Total	$35K - $160K

---

Hidden Costs That Blow Up Budgets

Beyond the standard cost categories, several expenses are routinely underbudgeted or entirely overlooked in initial trial budgets. These are the costs that cause budget overruns.

1. Protocol Amendments: $50K - $250K+ per Amendment

Protocol amendments are among the most expensive and disruptive events in a clinical trial. Each amendment triggers a cascade of downstream costs:

• Additional IRB/ethics committee review and approval ($2K-$10K per site)
• Updated informed consent forms and re-consenting enrolled patients
• Regulatory re-submissions (FDA IDE supplement if SR device)
• Site re-training on amended procedures
• Potential database modifications and data migration
• CRO change order fees

Industry data suggests that each protocol amendment costs $50K to $250K+ in direct and indirect costs. Studies with three or more amendments see total costs increase by 20-40%.

Mitigation: Invest more time in protocol design upfront. Conduct thorough literature reviews, consult key opinion leaders, and use Pre-Sub feedback to minimize the need for amendments.

2. Enrollment Delays: $30K - $100K+ per Month

Enrollment delays are the most common cause of trial budget overruns. Every month that a trial extends beyond its planned timeline incurs ongoing costs:

Monthly Cost During Extension	Estimated Range
Site maintenance (per site)	$2K - $8K per site per month
CRO ongoing management fees	$10K - $40K per month
Data management and monitoring	$5K - $20K per month
Study insurance continuation	$2K - $10K per month
Regulatory maintenance	$2K - $5K per month
Total monthly cost of delay (10-site study)	$30K - $100K+

A six-month enrollment delay on a 10-site pivotal study can add $180K to $600K+ to the budget.

Mitigation: Conduct realistic enrollment feasibility assessments. Budget for more sites than you think you need. Consider adaptive enrollment strategies.

3. Physician Consulting: $150 - $600+ per Hour

Key opinion leader (KOL) and physician consulting fees are a necessary part of trial design and execution, but they accumulate quickly:

Consulting Activity	Typical Rate	Estimated Hours	Total Cost
Protocol development input	$300 - $600/hr	20 - 60 hours	$6K - $36K
Endpoint adjudication (CEC member)	$200 - $500/hr	Ongoing	$20K - $80K+
Data Safety Monitoring Board (DSMB)	$200 - $500/hr per member	Periodic meetings	$30K - $100K+
Publication planning	$150 - $400/hr	20 - 40 hours	$3K - $16K

4. Independent Core Laboratory Analysis: $100K - $500K+

Many medical device trials -- particularly cardiovascular, orthopedic, and ophthalmology studies -- collect imaging data that requires standardized analysis by an independent core laboratory.

Core Lab Service	Typical Cost
Imaging protocol development	$15K - $40K
Site training and qualification	$10K - $30K
Per-patient image analysis	$500 - $3,000 per patient
Quality control and adjudication	$10K - $30K
Final dataset and report	$15K - $40K
Total (100-patient study)	$100K - $500K+

The core lab cost scales with both patient count and the number of imaging timepoints. A study with angiographic, CT, and ultrasound endpoints at baseline, 6 months, and 12 months will be at the high end of this range.

5. Inflation and Foreign Exchange: 3-7% per Year

Multi-year trials must account for inflation and, for international studies, currency fluctuations:

• Budget a minimum 3% annual inflation rate for all cost categories
• For EU studies, add VAT of 12-25% on research services depending on the country
• For studies spanning multiple currencies, consider hedging strategies or budgeting in local currency with a conversion buffer

6. Investigational Device Manufacturing and Supply: $50K - $500K+

The cost of manufacturing clinical-grade devices for the trial is separate from development costs:

Device Supply Component	Typical Cost
Clinical-grade manufacturing (per unit)	$500 - $10,000+
Sterilization and packaging	$50 - $500 per unit
Labeling (investigational)	$10 - $100 per unit
Shipping and logistics (per site)	$2K - $10K per shipment
Device tracking and accountability	$5K - $20K
Total (100-patient study)	$50K - $500K+

---

How Regulatory Pathway Affects Trial Budget

The regulatory pathway you pursue directly determines the scope and cost of your clinical trial program.

510(k) Clinical Data Requirements: $300K - $5M (when needed)

Most 510(k)s do not require clinical data. When data is required, the trial is typically smaller and shorter than what would be needed for PMA. The average 510(k) requires 1.58 review cycles, meaning most are cleared in one round with possible additional information requests.

Cost Component	Typical Range for 510(k) Clinical Study
Study scope	30-80 patients, single-arm
Number of sites	3-10
Follow-up	1-6 months
Total trial cost	$300K - $5M
510(k) user fee (FY 2026)	$26,067 standard / $6,517 small business
Pre-Sub meeting	No fee

De Novo Clinical Data Requirements: $500K - $10M

Cost Component	Typical Range for De Novo Clinical Study
Study scope	30-150 patients, single-arm or RCT
Number of sites	5-15
Follow-up	3-12 months
Total trial cost	$500K - $10M
De Novo user fee (FY 2026)	$173,782 standard / $43,446 small business
Pre-Sub meeting	No fee

PMA Clinical Data Requirements: $5M - $50M+

Cost Component	Typical Range for PMA Clinical Program
Feasibility study	$500K - $5M
Pivotal study	$2M - $20M+
Total clinical program	$5M - $50M+
PMA user fee (FY 2026)	$579,272 standard / $144,818 small business
Annual periodic reporting	$20,275 standard / $5,069 small business
Panel-track supplement (if needed)	$463,418 standard / $115,855 small business

FY 2026 FDA User Fee Reference

All fees below are for the fiscal year running October 1, 2025 through September 30, 2026:

Submission Type	Standard Fee	Small Business Fee
Establishment registration (annual)	$11,423	$11,423 (no reduction; waiver possible for qualifying small businesses)
510(k)	$26,067	$6,517
513(g)	$7,820	$3,910
De Novo classification request	$173,782	$43,446
PMA / PDP / PMR / BLA	$579,272	$144,818
Panel-track supplement	$463,418	$115,855
180-day supplement	$86,891	$21,723
Real-time supplement	$40,549	$10,137
30-day notice	$9,268	$4,634
Annual periodic reporting (Class III)	$20,275	$5,069

Notable changes from FY 2025: the establishment registration fee increased 23% (from $9,280 to $11,423), and PMA fees increased approximately 7% (from $540,783 to $579,272). All application fees increased roughly 7% year-over-year under the MDUFA V inflation adjustment formula.

Small business fee relief: Businesses with gross receipts and sales of $100 million or less (including affiliates) qualify for reduced fees at 25% of standard rates. Businesses with $30 million or less in gross receipts may qualify for a one-time waiver of their first PMA/PDP/PMR/BLA fee. For FY 2026, a new provision allows qualifying small businesses with $1 million or less in gross receipts to request a waiver of the establishment registration fee if they can demonstrate financial hardship.

---

Recommended Reading

SaMD Clinical Evaluation: How to Generate and Document Clinical Evidence for Software as a Medical Device Under FDA and EU MDR

Digital Health & AI Clinical Evidence2026-05-12 · 14 min read

Medicare Coverage for IDE Studies: How to Offset Trial Costs

One of the most significant -- and most frequently overlooked -- opportunities to reduce clinical trial costs is Medicare reimbursement for routine care costs in FDA-approved IDE studies.

How It Works

When FDA approves an Investigational Device Exemption (IDE), it assigns the device to one of two categories:

Category A (Experimental): Devices for which initial questions of safety and effectiveness have not been resolved. Medicare covers routine care items and services furnished during the study but does not cover the investigational device itself.

Category B (Non-experimental/Investigational): Devices for which initial questions of safety and effectiveness have been resolved (often newer generations of proven technologies). Medicare covers both routine care and the investigational device, subject to CMS approval.

The Financial Impact

The financial impact of Medicare coverage can be substantial. In a study enrolling Medicare-age patients, routine care costs -- hospital stays, physician visits, diagnostic tests, and follow-up care -- can represent 40-60% of total per-patient costs. For a Category B IDE study, the device cost may also be covered.

Consider a 100-patient pivotal study where 40 patients are Medicare beneficiaries:

Scenario	Without Medicare Coverage	With Category B Coverage
Routine care costs per patient	$15,000 - $30,000	Reimbursed by Medicare
Device cost per patient	$5,000 - $10,000	Reimbursed by Medicare (Category B)
Total savings for 40 Medicare patients	--	$800K - $1.6M+

How to Obtain Medicare Coverage

To obtain Medicare coverage for your IDE study:

1. Factor reimbursement into protocol development. Design the protocol with CMS coverage criteria in mind from the beginning. Include all information CMS needs for review.

2. Review your category designation. Understand whether FDA has assigned your device to Category A or B. Category B provides more comprehensive coverage.

3. Submit a complete request packet to CMS. After receiving IDE approval from FDA, submit a coverage request to CMS (or its designated Medicare Administrative Contractor) including the FDA approval letter, study protocol, and beneficiary information.

4. Budget time for CMS review. Allow adequate time in your study timeline for CMS submission preparation, review, and potential re-review. Do not assume immediate coverage.

5. Ensure each site submits its own notification. Each participating site must submit a written coverage request to its local Medicare contractor before submitting claims.

The RAPID Coverage Pathway (2026)

In 2026, CMS and FDA launched the RAPID (Regulatory Alignment for Predictable and Immediate Device) Coverage Pathway, designed to accelerate Medicare coverage for breakthrough medical devices. Under this pathway:

• Coverage decisions may be made within approximately 2 months post-approval
• FDA and CMS align evidence requirements early in development
• Devices under IDE study that enroll Medicare beneficiaries and evaluate clinical outcomes agreed upon by both agencies may qualify
• Applicable devices include Breakthrough Device-designated Class III devices and certain Class II devices in the FDA TAP program

This pathway significantly reduces the gap between FDA market authorization and Medicare reimbursement, which historically has taken a year or longer.

---

7 Strategies to Reduce Clinical Trial Cost Without Compromising Data Quality

Strategy 1: Confirm Whether Clinical Data Is Actually Required

The most effective cost-saving strategy is also the simplest: confirm that you need a clinical trial before starting one. File a Pre-Submission meeting request with FDA to get written feedback on your clinical evidence requirements. For 510(k) devices, this alone can save $300K to $5M if FDA confirms that non-clinical data is sufficient.

Savings potential: $300K - $5M+ (entire trial cost avoided)

Strategy 2: Use a Central IRB

For multi-site studies, using a single central IRB (rather than individual site IRBs) reduces fees, shortens startup timelines, and eliminates redundant reviews. Under the 2018 NIH Single IRB Policy and FDA's harmonized guidance, central IRB review is now standard for multi-site studies.

Savings potential: $10K - $50K for a 10-site study, plus 1-3 months faster startup

Strategy 3: Optimize Site Count vs. Enrollment Speed

More sites speed enrollment but increase fixed costs. Fewer sites reduce overhead but extend the timeline. Model the trade-off quantitatively:

Approach	Sites	Startup Cost	Enrollment Duration	Monthly Ongoing Cost	Total Cost Implication
Minimum sites	2-3	$70K - $200K	18-24 months	$30K - $60K/mo	Higher due to extended duration
Balanced	5-8	$175K - $500K	8-14 months	$40K - $80K/mo	Generally optimal
Maximum sites	15-20+	$525K - $1M+	4-8 months	$60K - $120K/mo	Higher due to site overhead

For most device studies, 5-8 well-selected sites provides the optimal balance between startup cost and enrollment efficiency.

Strategy 4: Negotiate CRO Fees with Competing Bids

CRO pricing varies substantially. Obtain at least three competitive bids, and negotiate on specific line items rather than accepting a lump-sum proposal. Key areas for negotiation:

• Fixed-fee vs. time-and-materials pricing (prefer fixed-fee where possible)
• Pass-through costs and markup percentages
• Change order provisions and rates
• Payment milestones tied to enrollment and study milestones
• Termination for convenience clauses

Savings potential: 15-30% reduction in CRO costs

Strategy 5: Leverage Real-World Evidence Where Possible

FDA's framework for accepting real-world evidence (RWE) has expanded significantly. For some 510(k) submissions, real-world data from registries, electronic health records, or published clinical data may supplement or partially replace a prospective clinical trial.

Discuss RWE strategies in your Pre-Submission meeting. Even if RWE cannot replace the trial entirely, it may reduce the number of patients or duration of follow-up needed.

Savings potential: $100K - $2M+ depending on available data

Strategy 6: Pursue Medicare Coverage for IDE Studies

As detailed in the previous section, obtaining CMS approval for Medicare coverage of routine care costs (and potentially the device itself for Category B studies) can offset a substantial portion of per-patient costs.

Savings potential: $800K - $1.6M+ for studies enrolling Medicare-age patients

Strategy 7: Use Adaptive and Pragmatic Trial Designs

Adaptive trial designs allow pre-specified modifications to the study based on interim data without requiring full protocol amendments. This can reduce the number of patients needed, shorten follow-up duration, and minimize the disruption and cost of protocol changes.

Pragmatic design elements -- broader inclusion criteria, simplified data collection, and integration with routine clinical care -- can reduce per-patient costs and accelerate enrollment.

Savings potential: 15-30% reduction in total trial cost

---

Comprehensive Budget Planning Table

The following table provides a consolidated reference for budgeting a medical device clinical trial in 2026, organized by study phase and cost category.

Complete Cost Reference by Study Size

Cost Category	Small (EFS, 20 patients)	Medium (Pilot, 50 patients)	Large (Pivotal, 100 patients)
Per-patient costs	$240K ($12K each)	$900K ($18K each)	$2.5M-$3M ($25K-$30K each)
Site startup and management	$40K (2 sites)	$150K (5 sites)	$400K (10 sites)
CRO management and monitoring	$180K	$400K	$1.2M
Data management and statistics	$90K	$180K	$600K
Regulatory and IDE support	$80K	$120K	$200K
IRB fees and insurance	$90K	$150K	$300K
Core lab (if applicable)	$0 - $50K	$100K - $300K	$200K - $500K
Investigational device supply	$20K - $50K	$50K - $150K	$100K - $300K
Physician consulting / DSMB / CEC	$20K - $40K	$50K - $100K	$150K - $300K
Technology and systems	$20K - $40K	$40K - $80K	$80K - $150K
Contingency (10-15%)	$80K - $100K	$200K - $250K	$550K - $700K
Estimated total	~$700K - $1.1M	~$2.2M - $2.9M	~$5.8M - $7.7M

Note: The contingency line item of 10-15% is the minimum recommended buffer. Industry practice for early-stage companies is to budget 20-25% contingency given the higher likelihood of enrollment delays and protocol amendments.

---

Recommended Reading

EU Breakthrough Device (BtX) Designation: Complete Guide to MDCG 2025-9 and the EMA Pilot Program

Regulatory EU MDR / IVDR2026-05-08 · 11 min read

Budget Planning Checklist

Use this checklist to ensure your clinical trial budget accounts for all cost categories:

Pre-Study Costs:

• Pre-Submission meeting preparation and attendance
• IDE application preparation and FDA fees
• Preclinical testing to support IDE (bench, animal)
• Regulatory consulting for clinical strategy
• Protocol development (statistician, KOL input, CRO)
• Investigational device manufacturing and supply
• Clinical trial insurance and subject injury coverage

Site-Related Costs:

• Site feasibility assessments
• Site contract and budget negotiation (per site)
• IRB review fees (central or per-site)
• Site initiation visits
• Investigator training
• Equipment shipping, setup, and maintenance
• Ongoing site management fees

Patient-Related Costs:

• Patient screening and enrollment
• Procedure / implantation costs (per patient)
• Follow-up visits (number of visits x per-visit cost)
• Investigator fees
• Patient travel reimbursement and stipends
• Adverse event management budget

CRO and Monitoring Costs:

• CRO project management fees
• Clinical monitoring visits and travel
• Site closeout visits
• Medical monitoring and safety oversight
• CRO change order budget

Data and Analysis Costs:

• Electronic Data Capture (EDC) system
• Database design, build, and validation
• Data entry and query resolution
• Statistical analysis plan (SAP) development
• Interim analysis (if planned)
• Final statistical analysis
• Clinical study report (CSR) writing

Specialized Services:

• Independent core laboratory (if imaging endpoints)
• Clinical Events Committee (CEC) adjudication
• Data Safety Monitoring Board (DSMB)
• Patient recruitment advertising and outreach

Regulatory and Compliance Costs:

• IDE maintenance (amendments, annual reports)
• Continuing IRB review (annual)
• FDA user fees (510(k), De Novo, or PMA submission)
• Establishment registration fee ($11,423 for FY 2026)
• Annual periodic reporting fee (Class III devices: $20,275/$5,069)

Overhead and Contingency:

• Inflation adjustment (minimum 3% per year for multi-year studies)
• VAT for international sites (12-25% depending on country)
• Currency exchange buffer (international studies)
• Contingency reserve (minimum 10-15%; 20-25% for first trials)
• Legal review of contracts and agreements

---

The Bottom Line

Medical device clinical trial costs in 2026 span an enormous range: from roughly $300,000 for a minimal early feasibility study to over $20 million for a large pivotal trial supporting PMA. The most critical factors driving cost are the number of patients, number of sites, duration of follow-up, and the complexity of the device and procedure.

Three principles will serve you better than any single cost estimate:

First, confirm that you need a trial. A Pre-Submission meeting with FDA is free and can save your entire trial budget if FDA confirms that non-clinical data is sufficient. For most 510(k) devices, this is exactly what happens.

Second, budget with rigor and contingency. Build your estimate from the bottom up, using the per-category figures in this guide as your starting point. Add a contingency reserve of at least 15% (20-25% for first-time sponsors). The most commonly underbudgeted categories are site startup, enrollment delays, and protocol amendments.

Third, pursue every legitimate cost offset. Medicare coverage for Category B IDE studies, real-world evidence strategies, adaptive trial designs, and competitive CRO bidding can collectively reduce your total trial cost by 25-40%.

The companies that manage clinical trial budgets successfully are not the ones that spend the least -- they are the ones that spend deliberately, with full visibility into where every dollar goes.